Global Erectile Dysfunction Drugs Market is expected to grow at a CAGR of 3.4% during the forecast period. Global Erectile Dysfunction Drugs Market is expected to reach US$ 2.56 Bn. by 2029. Although other types of medical treatments for erectile dysfunction (e.g. intracavernosal injections, intraurethral suppositories) have been available for many years, their use has been associated with specific adverse events (e.g. local pain, priapism, fibrosis) and low compliance rates due to the invasive nature of these therapies. Alprostadil, papaverine, and organic nitrates are examples of topical treatments that have been approved by medical bodies as alternate possibilities due to their less intrusive routes of delivery. Hormonal treatments, vacuum constriction devices, and surgical therapies are further second-line therapeutic options for people with persistent ED or who cannot take PDE-5 medication (e.g. penile prosthesis implants, penile arterial bypass). Globally, erectile dysfunction (ED) has become increasingly common, even among young individuals, and is a growing health problem that has a substantial impact on men's quality of life. The number of ED cases globally is expected to reach nearly 322 million by the end of 2025. Erectile dysfunction drugs (EDMs) are increasingly being used as a sexual enhancement aid among men who do not have a medical justification, as per overwhelming evidence. Recreational EDM usage has been linked to increased sexual risk behaviors, a higher risk of STIs, including HIV infection, and a high prevalence of simultaneous illegal substance consumption. The Food and Drug Administration (FDA) now approves three oral drugs for the treatment of erectile dysfunction (ED): sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra). These erectile dysfunction drugs are widely accepted and effective for treating ED of diverse etiologies, and it is estimated that sildenafil alone has been prescribed to over 25 million men globally. The Erectile Dysfunction Drugs Market is segmented based on Product, End-user, and Region. The growth of various segments helps the report users in acquiring knowledge of the many growth factors expected to be prevalent throughout the market and develop different strategies to help identify core application areas and the gap in the target market. The report provides an in-depth analysis of the market and contains meaningful insights, facts, historical data, and statistically supported and industry-validated market statistics. It also includes estimates based on an appropriate set of assumptions and methodologies.To know about the Research Methodology :- Request Free Sample Report The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding global erectile dysfunction drugs market dynamics, structure by identifying and analysing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the global erectile dysfunction drugs market. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis. Growing elderly population and high rate of chronic diseases such as kidney failure, hormonal imbalance, diabetes, hypertension, and neurological disorders are increasing demand for erectile dysfunction drugs globally. Additionally, increasing awareness among patients about erectile dysfunction and availability of treatment are contributing significantly towards the growth of erectile dysfunction drugs market. Then, even with of increasing demand for erectile dysfunction drugs, the global market is facing decline owing to patent expiry of market blockbuster drugs such as Viagra etc. The key factors that are helping the growth of global erectile dysfunction drugs market include a rise in the competition among the major market players, increasing number of men suffering from erectile dysfunction, and a number of drugs available in the market. Though, some factors that can harm the market growth contain the availability of counterfeit drugs, the increasing manufactures of generic drugs in the market, and patent expiry of a number of blockbuster drugs.
Viagra accounted for over 45% of the total revenue in 2021. It is mostly considered as the first line of treatment for erectile dysfunction. Brand loyalty and benefits associated with this drug such as high efficacy and effectiveness are the major factors attributing for its large market share. Pharmaceutical companies segment is expected to dominate the global erectile dysfunction drug market during the forecast period. Easy availability of erectile dysfunction drugs at pharmaceutical companies, low price of the drugs, and expansion of leading retail pharmacy chains across the globe drive the segment. The hospital pharmacies segment held the second largest share of the global erectile dysfunction drugs market. Region-wise, North America dominated the global erectile dysfunction drugs market in 2021 followed by Europe. This growth in the market is attributable to the high awareness and the increasing research and development activities. Moreover, factors such as the presence of favourable medical reimbursement policies, the high prevalence of erectile dysfunction, and a growing geriatric population are fuelling the growth of dysfunction drugs market presence in North America.
Global Erectile Dysfunction Drugs Market Scope: Inquire before buying
Global Erectile Dysfunction Drugs Market, by Product
• Viagra • Cialis • Levitra • Stendra • ZydenaGlobal Erectile Dysfunction Drugs Market, by End-user
• Pharmaceutical Companies • Hospitals • Clinics • OthersGlobal Erectile Dysfunction Drugs Market, by Region
• North America • Europe • Asia Pacific • Middle East and Africa • South AmericaGlobal Erectile Dysfunction Drugs Market Key Players
• Apricus Biosciences • Bayer AG • Cristália, • Eli Lilly and Company, Inc. • Pfizer, Inc. • Dong-A-Pharmaceutical Co., Ltd. • S.K. Chemicals Co., Ltd. • Vivus, Inc. • Teva Pharmaceutical Industries Ltd. • Meda Pharmaceuticals, Inc. • Ferring Pharmaceuticals • GlaxoSmithKline PLC • Metuchen Pharmaceuticals LLC • Boston Scientific • Coloplast • Viatris • Produtos Quimicos Farmaceuticos Ltd. Frequently Asked Questions: 1. Which region has the largest share in Global Erectile Dysfunction Drugs Market? Ans: North America region held the highest share in 2021. 2. What is the growth rate of Global Erectile Dysfunction Drugs Market? Ans: The Global Erectile Dysfunction Drugs Market is growing at a CAGR of 3.4% during forecasting period 2022-2029. 3. What is scope of the Global Erectile Dysfunction Drugs market report? Ans: Global Erectile Dysfunction Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Erectile Dysfunction Drugs market? Ans: The important key players in the Global Erectile Dysfunction Drugs Market are – Apricus Biosciences, Bayer AG, Cristália,, Eli Lilly and Company, Inc., Pfizer, Inc., Dong-A-Pharmaceutical Co., Ltd., S.K. Chemicals Co., Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, Inc., Ferring Pharmaceuticals, GlaxoSmithKline PLC, Metuchen Pharmaceuticals LLC, Boston Scientific, Coloplast, Viatris, and Produtos Quimicos Farmaceuticos Ltd. 5. What is the study period of this market? Ans: The Global Erectile Dysfunction Drugs Market is studied from 2021 to 2029.
Global Erectile Dysfunction Drugs Market
1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Erectile Dysfunction Drugs Market Size, by Market Value (US$ Bn) and by Volume (Units) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies in Global Erectile Dysfunction Drugs Market 5. Supply Side and Demand Side Indicators 6. Global Erectile Dysfunction Drugs Market Analysis and Forecast 6.1. Global Erectile Dysfunction Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Erectile Dysfunction Drugs Market Analysis and Forecast, by Product 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Erectile Dysfunction Drugs Market Value Share Analysis, by Product 7.4. Global Erectile Dysfunction Drugs Market Size (US$ Bn) Forecast, by Product 7.5. Global Erectile Dysfunction Drugs Market Analysis, by Product 7.6. Global Erectile Dysfunction Drugs Market Attractiveness Analysis, by Product 8. Global Erectile Dysfunction Drugs Market Analysis and Forecast, by End user 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Erectile Dysfunction Drugs Market Value Share Analysis, by End user 8.4. Global Erectile Dysfunction Drugs Market Size (US$ Bn) Forecast, by End user 8.5. Global Erectile Dysfunction Drugs Market Analysis, by End user 8.6. Global Erectile Dysfunction Drugs Market Attractiveness Analysis, by End user 9. Global Erectile Dysfunction Drugs Market Analysis, by Region 9.1. Global Erectile Dysfunction Drugs Market Value Share Analysis, by Region 9.2. Global Erectile Dysfunction Drugs Market Size (US$ Bn) Forecast, by Region 9.3. Global Erectile Dysfunction Drugs Market Attractiveness Analysis, by Region 10. North America Erectile Dysfunction Drugs Market Analysis 10.1. Key Findings 10.2. North America Erectile Dysfunction Drugs Market Overview 10.3. North America Erectile Dysfunction Drugs Market Value Share Analysis, by Product 10.4. North America Erectile Dysfunction Drugs Market Forecast, by Product 10.4.1. Viagra 10.4.2. Cialis 10.4.3. Levitra 10.4.4. Stendra 10.4.5. Zydena 10.5. North America Erectile Dysfunction Drugs Market Value Share Analysis, by End user 10.6. North America Erectile Dysfunction Drugs Market Forecast, by End user 10.6.1. Pharmaceutical Companies 10.6.2. Hospitals 10.6.3. Clinic 10.6.4. Others 10.7. North America Erectile Dysfunction Drugs Market Value Share Analysis, by Country 10.8. North America Erectile Dysfunction Drugs Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Erectile Dysfunction Drugs Market Analysis, by Country 10.10. U.S. Erectile Dysfunction Drugs Market Forecast, by Product 10.10.1. Viagra 10.10.2. Cialis 10.10.3. Levitra 10.10.4. Stendra 10.10.5. Zydena 10.11. U.S. Erectile Dysfunction Drugs Market Forecast, by End user 10.11.1. Pharmaceutical Companies 10.11.2. Hospitals 10.11.3. Clinic 10.11.4. Others 10.12. Canada Erectile Dysfunction Drugs Market Forecast, by Product 10.12.1. Viagra 10.12.2. Cialis 10.12.3. Levitra 10.12.4. Stendra 10.12.5. Zydena 10.13. Canada Erectile Dysfunction Drugs Market Forecast, by End user 10.13.1. Pharmaceutical Companies 10.13.2. Hospitals 10.13.3. Clinic 10.13.4. Others 10.14. North America Erectile Dysfunction Drugs Market Attractiveness Analysis 10.14.1. By Product 10.14.2. By End user 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Developments 11. Europe Erectile Dysfunction Drugs Market Analysis 11.1. Key Findings 11.2. Europe Erectile Dysfunction Drugs Market Overview 11.3. Europe Erectile Dysfunction Drugs Market Value Share Analysis, by Product 11.4. Europe Erectile Dysfunction Drugs Market Forecast, by Product 11.4.1. Viagra 11.4.2. Cialis 11.4.3. Levitra 11.4.4. Stendra 11.4.5. Zydena 11.5. Europe Erectile Dysfunction Drugs Market Value Share Analysis, by End user 11.6. Europe Erectile Dysfunction Drugs Market Forecast, by End user 11.6.1. Pharmaceutical Companies 11.6.2. Hospitals 11.6.3. Clinic 11.6.4. Others 11.7. Europe Erectile Dysfunction Drugs Market Value Share Analysis, by Country 11.8. Europe Erectile Dysfunction Drugs Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Erectile Dysfunction Drugs Market Analysis, by Country 11.10. Germany Erectile Dysfunction Drugs Market Forecast, by Product 11.10.1. Viagra 11.10.2. Cialis 11.10.3. Levitra 11.10.4. Stendra 11.10.5. Zydena 11.11. Germany Erectile Dysfunction Drugs Market Forecast, by End user 11.11.1. Pharmaceutical Companies 11.11.2. Hospitals 11.11.3. Clinic 11.11.4. Others 11.12. U.K. Erectile Dysfunction Drugs Market Forecast, by Product 11.12.1. Viagra 11.12.2. Cialis 11.12.3. Levitra 11.12.4. Stendra 11.12.5. Zydena 11.13. U.K. Erectile Dysfunction Drugs Market Forecast, by End user 11.13.1. Pharmaceutical Companies 11.13.2. Hospitals 11.13.3. Clinic 11.13.4. Others 11.14. France Erectile Dysfunction Drugs Market Forecast, by Product 11.14.1. Viagra 11.14.2. Cialis 11.14.3. Levitra 11.14.4. Stendra 11.14.5. Zydena 11.15. France Erectile Dysfunction Drugs Market Forecast, by End user 11.15.1. Pharmaceutical Companies 11.15.2. Hospitals 11.15.3. Clinic 11.15.4. Others 11.16. Italy Erectile Dysfunction Drugs Market Forecast, by Product 11.16.1. Viagra 11.16.2. Cialis 11.16.3. Levitra 11.16.4. Stendra 11.16.5. Zydena 11.17. Italy Erectile Dysfunction Drugs Market Forecast, by End user 11.17.1. Pharmaceutical Companies 11.17.2. Hospitals 11.17.3. Clinic 11.17.4. Others 11.18. Spain Erectile Dysfunction Drugs Market Forecast, by Product 11.18.1. Viagra 11.18.2. Cialis 11.18.3. Levitra 11.18.4. Stendra 11.18.5. Zydena 11.19. Spain Erectile Dysfunction Drugs Market Forecast, by End user 11.19.1. Pharmaceutical Companies 11.19.2. Hospitals 11.19.3. Clinic 11.19.4. Others 11.20. Rest of Europe Erectile Dysfunction Drugs Market Forecast, by Product 11.20.1. Viagra 11.20.2. Cialis 11.20.3. Levitra 11.20.4. Stendra 11.20.5. Zydena 11.21. Rest Of Europe Erectile Dysfunction Drugs Market Forecast, by End user 11.21.1. Pharmaceutical Companies 11.21.2. Hospitals 11.21.3. Clinic 11.21.4. Others 11.22. Europe Erectile Dysfunction Drugs Market Attractiveness Analysis 11.22.1. By Product 11.22.2. By End user 11.23. PEST Analysis 11.24. Key Trends 11.25. Key Developments 12. Asia Pacific Erectile Dysfunction Drugs Market Analysis 12.1. Key Findings 12.2. Asia Pacific Erectile Dysfunction Drugs Market Overview 12.3. Asia Pacific Erectile Dysfunction Drugs Market Value Share Analysis, by Product 12.4. Asia Pacific Erectile Dysfunction Drugs Market Forecast, by Product 12.4.1. Viagra 12.4.2. Cialis 12.4.3. Levitra 12.4.4. Stendra 12.4.5. Zydena 12.5. Asia Pacific Erectile Dysfunction Drugs Market Value Share Analysis, by End user 12.6. Asia Pacific Erectile Dysfunction Drugs Market Forecast, by End user 12.6.1. Pharmaceutical Companies 12.6.2. Hospitals 12.6.3. Clinic 12.6.4. Others 12.7. Asia Pacific Erectile Dysfunction Drugs Market Value Share Analysis, by Country 12.8. Asia Pacific Erectile Dysfunction Drugs Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Erectile Dysfunction Drugs Market Analysis, by Country 12.10. China Erectile Dysfunction Drugs Market Forecast, by Product 12.10.1. Viagra 12.10.2. Cialis 12.10.3. Levitra 12.10.4. Stendra 12.10.5. Zydena 12.11. China Erectile Dysfunction Drugs Market Forecast, by End user 12.11.1. Pharmaceutical Companies 12.11.2. Hospitals 12.11.3. Clinic 12.11.4. Others 12.12. India Erectile Dysfunction Drugs Market Forecast, by Product 12.12.1. Viagra 12.12.2. Cialis 12.12.3. Levitra 12.12.4. Stendra 12.12.5. Zydena 12.13. India Erectile Dysfunction Drugs Market Forecast, by End user 12.13.1. Pharmaceutical Companies 12.13.2. Hospitals 12.13.3. Clinic 12.13.4. Others 12.14. Japan Erectile Dysfunction Drugs Market Forecast, by Product 12.14.1. Viagra 12.14.2. Cialis 12.14.3. Levitra 12.14.4. Stendra 12.14.5. Zydena 12.15. Japan Erectile Dysfunction Drugs Market Forecast, by End user 12.15.1. Pharmaceutical Companies 12.15.2. Hospitals 12.15.3. Clinic 12.15.4. Others 12.16. ASEAN Erectile Dysfunction Drugs Market Forecast, by Product 12.16.1. Viagra 12.16.2. Cialis 12.16.3. Levitra 12.16.4. Stendra 12.16.5. Zydena 12.17. ASEAN Erectile Dysfunction Drugs Market Forecast, by End user 12.17.1. Pharmaceutical Companies 12.17.2. Hospitals 12.17.3. Clinic 12.17.4. Others 12.18. Rest of Asia Pacific Erectile Dysfunction Drugs Market Forecast, by Product 12.18.1. Viagra 12.18.2. Cialis 12.18.3. Levitra 12.18.4. Stendra 12.18.5. Zydena 12.19. Rest of Asia Pacific Erectile Dysfunction Drugs Market Forecast, by End user 12.19.1. Pharmaceutical Companies 12.19.2. Hospitals 12.19.3. Clinic 12.19.4. Others 12.20. Asia Pacific Erectile Dysfunction Drugs Market Attractiveness Analysis 12.20.1. By Product 12.20.2. By End user 12.21. PEST Analysis 12.22. Key Trends 12.23. Key Developments 13. Middle East & Africa Erectile Dysfunction Drugs Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Erectile Dysfunction Drugs Market Overview 13.3. Middle East & Africa Erectile Dysfunction Drugs Market Value Share Analysis, by Product 13.4. Middle East & Africa Erectile Dysfunction Drugs Market Forecast, by Product 13.4.1. Viagra 13.4.2. Cialis 13.4.3. Levitra 13.4.4. Stendra 13.4.5. Zydena 13.5. Middle East & Africa Erectile Dysfunction Drugs Market Value Share Analysis, by End user 13.6. Middle East & Africa Erectile Dysfunction Drugs Market Forecast, by End user 13.6.1. Pharmaceutical Companies 13.6.2. Hospitals 13.6.3. Clinic 13.6.4. Others 13.7. Middle East & Africa Erectile Dysfunction Drugs Market Value Share Analysis, by Country 13.8. Middle East & Africa Erectile Dysfunction Drugs Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Erectile Dysfunction Drugs Market Analysis, by Country 13.10. GCC Erectile Dysfunction Drugs Market Forecast, by Product 13.10.1. Viagra 13.10.2. Cialis 13.10.3. Levitra 13.10.4. Stendra 13.10.5. Zydena 13.11. GCC Erectile Dysfunction Drugs Market Forecast, by End user 13.11.1. Pharmaceutical Companies 13.11.2. Hospitals 13.11.3. Clinic 13.11.4. Others 13.12. South Africa Erectile Dysfunction Drugs Market Forecast, by Product 13.12.1. Viagra 13.12.2. Cialis 13.12.3. Levitra 13.12.4. Stendra 13.12.5. Zydena 13.13. South Africa Erectile Dysfunction Drugs Market Forecast, by End user 13.13.1. Pharmaceutical Companies 13.13.2. Hospitals 13.13.3. Clinic 13.13.4. Others 13.14. Rest of Middle East & Africa Erectile Dysfunction Drugs Market Forecast, by Product 13.14.1. Viagra 13.14.2. Cialis 13.14.3. Levitra 13.14.4. Stendra 13.14.5. Zydena 13.15. Rest of Middle East & Africa Erectile Dysfunction Drugs Market Forecast, by End user 13.15.1. Pharmaceutical Companies 13.15.2. Hospitals 13.15.3. Clinic 13.15.4. Others 13.16. Middle East & Africa Erectile Dysfunction Drugs Market Attractiveness Analysis 13.16.1. By Product 13.16.2. By End user 13.17. PEST Analysis 13.18. Key Trends 13.19. Key Developments 14. South America Erectile Dysfunction Drugs Market Analysis 14.1. Key Findings 14.2. South America Erectile Dysfunction Drugs Market Overview 14.3. South America Erectile Dysfunction Drugs Market Value Share Analysis, by Product 14.4. South America Erectile Dysfunction Drugs Market Forecast, by Product 14.4.1. Viagra 14.4.2. Cialis 14.4.3. Levitra 14.4.4. Stendra 14.4.5. Zydena 14.5. South America Erectile Dysfunction Drugs Market Value Share Analysis, by End user 14.6. South America Erectile Dysfunction Drugs Market Forecast, by End user 14.6.1. Pharmaceutical Companies 14.6.2. Hospitals 14.6.3. Clinic 14.6.4. Others 14.7. South America Erectile Dysfunction Drugs Market Value Share Analysis, by Country 14.8. South America Erectile Dysfunction Drugs Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. South America Erectile Dysfunction Drugs Market Analysis, by Country 14.10. Brazil Erectile Dysfunction Drugs Market Forecast, by Product 14.10.1. Viagra 14.10.2. Cialis 14.10.3. Levitra 14.10.4. Stendra 14.10.5. Zydena 14.11. Brazil Erectile Dysfunction Drugs Market Forecast, by End user 14.11.1. Pharmaceutical Companies 14.11.2. Hospitals 14.11.3. Clinic 14.11.4. Others 14.12. Mexico Erectile Dysfunction Drugs Market Forecast, by Product 14.12.1. Viagra 14.12.2. Cialis 14.12.3. Levitra 14.12.4. Stendra 14.12.5. Zydena 14.13. Mexico Erectile Dysfunction Drugs Market Forecast, by End user 14.13.1. Pharmaceutical Companies 14.13.2. Hospitals 14.13.3. Clinic 14.13.4. Others 14.14. Rest of South America Erectile Dysfunction Drugs Market Forecast, by Product 14.14.1. Viagra 14.14.2. Cialis 14.14.3. Levitra 14.14.4. Stendra 14.14.5. Zydena 14.15. Rest of South America Erectile Dysfunction Drugs Market Forecast, by End user 14.15.1. Pharmaceutical Companies 14.15.2. Hospitals 14.15.3. Clinic 14.15.4. Others 14.16. South America Erectile Dysfunction Drugs Market Attractiveness Analysis 14.16.1. By Product 14.16.2. By End user 14.17. PEST Analysis 14.18. Key Trends 14.19. Key Developments 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Apricus Biosciences 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Manufacturing Footprint 15.3.2. Bayer AG 15.3.3. Cristália, 15.3.4. Pfizer, Inc. 15.3.5. Dong-A-Pharmaceutical Co., Ltd. 15.3.6. S.K. Chemicals Co., Ltd. 15.3.7. Vivus, Inc. 15.3.8. Teva Pharmaceutical Industries Ltd. 15.3.9. Meda Pharmaceuticals, Inc. 15.3.10. Ferring Pharmaceuticals 15.3.11. GlaxoSmithKline PLC 15.3.12. Metuchen Pharmaceuticals LLC 15.3.13. Boston Scientific 15.3.14. Coloplast 15.3.15. Viatris 15.3.16. Produtos Quimicos Farmaceuticos Ltd. 15.3.17. Eli Lilly and Company, Inc. 16. Primary Key Insights